Jpmorgan Chase & CO Precigen, Inc. Transaction History

Jpmorgan Chase & CO

$1.1 Trillion
Q1 2024

A detailed history of Jpmorgan Chase & CO transactions in Precigen, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,294,704 shares of PGEN stock, worth $1.81 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,294,704

Previous 1,343,276 3.62%

Holding current value

$1.81 Million

Previous $1.8 Million 4.34%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$1.21 - $1.75 $58,772 - $85,001	-48,572 Reduced 3.62%	1,294,704 $1.88 Million
Q4 2023 Feb 12, 2024	SELL	$0.89 - $1.41 $530 - $840	-596 Reduced 0.04%	1,343,276 $1.8 Million
Q3 2023 Nov 14, 2023	BUY	$1.08 - $1.85 $152,416 - $261,083	141,126 Added 11.73%	1,343,872 $1.91 Million
Q2 2023 Aug 11, 2023	SELL	$0.96 - $1.4 $9,358 - $13,647	-9,748 Reduced 0.8%	1,202,746 $1.38 Million
Q1 2023 May 18, 2023	BUY	$0.88 - $2.19 $82,234 - $204,651	93,448 Added 8.35%	1,212,494 $1.29 Million

Q1 2023 May 11, 2023	SELL	$0.88 - $2.19 $50,235 - $125,018	-57,086 Reduced 4.85%	1,119,046 $1.19 Million
Q4 2022 Feb 13, 2023	SELL	$1.27 - $2.26 $7,228 - $12,863	-5,692 Reduced 0.48%	1,176,132 $1.79 Million
Q3 2022 Nov 14, 2022	SELL	$1.41 - $2.79 $755,191 - $1.49 Million	-535,597 Reduced 31.19%	1,181,824 $2.51 Million
Q2 2022 Aug 11, 2022	SELL	$1.15 - $2.53 $42,420 - $93,324	-36,887 Reduced 2.1%	1,717,421 $2.3 Million
Q1 2022 May 11, 2022	SELL	$1.91 - $3.98 $292,971 - $610,484	-153,388 Reduced 8.04%	1,754,308 $3.7 Million
Q4 2021 Feb 10, 2022	BUY	$3.53 - $5.5 $229,831 - $358,094	65,108 Added 3.53%	1,907,696 $7.08 Million
Q3 2021 Nov 12, 2021	BUY	$4.99 - $6.55 $9.19 Million - $12.1 Million	1,842,588 New	1,842,588 $9.19 Million

Others Institutions Holding PGEN

# of Institutions

141

Shares Held

145M

Call Options Held

208K

Put Options Held

43.7K

View Full List

About PRECIGEN, INC.

Ticker PGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 208,150,000
Market Cap $291M
Description
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...

More about PGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Precigen, Inc. Transaction History